

American Brachytherapy Society consensus guidelines permanent prostate brachytherapy

Brachytherapy

11, 6-19

DOI: [10.1016/j.brachy.2011.07.005](https://doi.org/10.1016/j.brachy.2011.07.005)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Two solutions for registration of ultrasound to MRI for image-guided prostate interventions. , 2012, 2012, 1129-32.		15
4	A novel curvilinear approach for prostate seed implantation. Medical Physics, 2012, 39, 1887-1892.	1.6	48
5	Implications of CT imaging for postplan quality assessment in prostate brachytherapy. Brachytherapy, 2012, 11, 435-440.	0.2	12
6	A survey of current clinical practice in permanent and temporary prostate brachytherapy: 2010 update. Brachytherapy, 2012, 11, 299-305.	0.2	35
7	Results of a Surgically Derived Nomogram to Predict Gleason Score Upgrading Applied to a Cohort of Patients With "Favorable-risk" Prostate Cancer Treated With Permanent Seed Brachytherapy. Urology, 2012, 80, 649-655.	0.5	8
8	Ultrasound"fluoroscopy registration for prostate brachytherapy dosimetry. Medical Image Analysis, 2012, 16, 1347-1358.	7.0	19
9	Assessment of I-125 seed implant accuracy when using the live-planning technique for low dose rate prostate brachytherapy. Radiation Oncology, 2012, 7, 196.	1.2	3
10	Educational Corner Prostate cancer brachytherapy: guidelines overview. Journal of Contemporary Brachytherapy, 2012, 2, 116-120.	0.4	19
11	<i>In vivo</i> dosimetry in brachytherapy. Medical Physics, 2013, 40, 070902.	1.6	145
12	Brachytherapy: Current Status and Future Strategies " Can High Dose Rate Replace Low Dose Rate and External Beam Radiotherapy?. Clinical Oncology, 2013, 25, 474-482.	0.6	76
13	Impact of experience and technical changes on acute urinary and rectal morbidity in low-dose prostate brachytherapy using loose seeds real-time implantation. Brachytherapy, 2013, 12, 589-595.	0.2	11
15	Re-implantation after insufficient primary 125-i permanent prostate brachytherapy. Radiation Oncology, 2013, 8, 194.	1.2	6
16	Comparison of 3 different postimplant dosimetry methods following permanent 125I prostate seed brachytherapy. Medical Dosimetry, 2013, 38, 309-314.	0.4	6
17	Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation. Radiotherapy and Oncology, 2013, 109, 241-245.	0.3	11
18	CT- and MRI-based seed localization in postimplant evaluation after prostate brachytherapy. Brachytherapy, 2013, 12, 580-588.	0.2	19
19	Focal brachytherapy for selected low-risk prostate cancers: A pilot study. Brachytherapy, 2013, 12, 331-337.	0.2	89
20	Improving prostate brachytherapy quality assurance with MRI"CT fusion"based sector analysis in a phase II prospective trial of men with intermediate-risk prostate cancer. Brachytherapy, 2013, 12, 401-407.	0.2	16
22	First report of transperineal polyethylene glycol hydrogel spacer use to curtail rectal radiation dose after permanent iodine-125 prostate brachytherapy. Brachytherapy, 2013, 12, 368-374.	0.2	30

#	ARTICLE	IF	CITATIONS
24	GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. <i>Radiotherapy and Oncology</i> , 2013, 107, 325-332.	0.3	236
25	Canadian Prostate Brachytherapy in 2012. <i>Canadian Urological Association Journal</i> , 2013, 7, 51.	0.3	19
26	Technical and dosimetric aspects of iodine-125 seed reimplantation in suboptimal prostate implants. <i>British Journal of Radiology</i> , 2013, 86, 20130058.	1.0	2
27	The phylogeny of permanent prostate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2013, 2, 89-92.	0.4	21
28	Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection. <i>Journal of Contemporary Brachytherapy</i> , 2013, 2, 63-69.	0.4	15
29	Haematuria after prostate brachytherapy. <i>BJU International</i> , 2013, 111, E319-24.	1.3	8
30	BrachyView: Tomographic reconstruction using Timepix detectors in post-implant dosimetry checks for permanent prostate brachytherapy implants. , 2013, , .		0
31	Interstitial Prostate Brachytherapy. , 2013, , .		1
32	Focal low-dose rate brachytherapy for the treatment of prostate cancer. <i>Cancer Management and Research</i> , 2013, 5, 315.	0.9	5
33	Evidence-based guideline recommendations on low-dose rate brachytherapy in patients with low- or intermediate-risk prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 7, 411.	0.3	10
34	Radiation Therapy Modalities in Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 414-421.	2.3	11
35	Prostate cancer as a paradigm of multidisciplinary approach? Highlights from the Italian young radiation oncologist meeting. <i>Tumori</i> , 2013, 99, 637-649.	0.6	18
36	External beam radiation therapy and a low-dose-rate brachytherapy boost without or with androgen deprivation therapy for prostate cancer. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2014, 40, 474-483.	0.7	9
37	Prostate Volume in Patients Undergoing Primary Surgical or Radiotherapeutic Management of Localized Adenocarcinoma: Implications for Design of Minimally Invasive Imaging and Treatment Devices for the Prostate. <i>OMICS Journal of Radiology</i> , 2014, 03, .	0.0	0
38	Variability in MRI vs. ultrasound measures of prostate volume and its impact on treatment recommendations for favorable-risk prostate cancer patients: a case series. <i>Radiation Oncology</i> , 2014, 9, 200.	1.2	12
39	Permanent Seed Implantation. <i>Medical Radiology</i> , 2014, , 187-210.	0.0	0
40	Feasibility of vibroacoustography with a quasi-2D ultrasound array transducer for detection and localizing of permanent prostate brachytherapy seeds: A pilot <i>ex vivo</i> study. <i>Medical Physics</i> , 2014, 41, 092902.	1.6	4
41	An image-guidance system for dynamic dose calculation in prostate brachytherapy using ultrasound and fluoroscopy. <i>Medical Physics</i> , 2014, 41, 091712.	1.6	18

#	ARTICLE	IF	CITATIONS
42	A Doseâ€”Response Analysis of Biochemical Control Outcomes After 125I Monotherapy for Patients With Favorable-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1069-1075.	0.4	18
43	AAPM and GECâ€”ESTRO guidelines for imageâ€”guided robotic brachytherapy: Report of Task Group 192. <i>Medical Physics</i> , 2014, 41, 101501.	1.6	78
44	Iodineâ€”125 thin seeds decrease prostate swelling during transperineal interstitial permanent prostate brachytherapy. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2014, 58, 109-116.	0.9	3
45	Modern Brachytherapy. <i>Seminars in Oncology</i> , 2014, 41, 831-847.	0.8	23
46	Quantifying the effect of seed orientation in postplanning dosimetry of lowâ€”doseâ€”rate prostate brachytherapy. <i>Medical Physics</i> , 2014, 41, 101704.	1.6	13
47	ACR Appropriateness Criteriaâ”® Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 278-288.	0.6	13
48	Dose heterogeneity correction for low-energy brachytherapy sources using dual-energy CT images. <i>Physics in Medicine and Biology</i> , 2014, 59, 5305-5316.	1.6	12
49	Multisector dosimetry in the immediate post-implant period: significant under dosage of the prostate base. <i>Journal of Contemporary Brachytherapy</i> , 2014, 1, 33-39.	0.4	7
50	Fiveâ€”year outcomes after iodineâ€”125 seed brachytherapy for lowâ€”risk prostate cancer at three cancer centres in the ^{UK}. <i>BJU International</i> , 2014, 113, 748-753.	1.3	17
51	Is tissue harmonic ultrasound imaging (THI) of the prostatic urethra and rectum superior to brightness (B) mode imaging? An observer study. <i>Physica Medica</i> , 2014, 30, 662-668.	0.4	5
52	The Quadrella: A Novel Approach in Analyzing Optimal Outcomes after Permanent Seed Prostate Brachytherapy. <i>Brachytherapy</i> , 2014, 13, S125.	0.2	0
53	The Quadrella: A novel approach to analyzing optimal outcomes after permanent seed prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2014, 111, 110-113.	0.3	5
54	Microfocus X-ray imaging of the internal geometry of brachytherapy seeds. <i>Applied Radiation and Isotopes</i> , 2014, 86, 13-20.	0.7	2
55	Time management in radiation oncology: evaluation of time, attendance of medical staff, and resources during radiotherapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 17-25.	1.0	6
56	¹⁰³Pd strings: Monte Carlo assessment of a new approach to brachytherapy source design. <i>Medical Physics</i> , 2014, 41, 011716.	1.6	9
57	Sector analysis of dosimetry of prostate cancer patients treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2014, 13, 369-374.	0.2	21
58	Target ablationâ€”Image-guided therapy in prostate cancer11Arnaud Marien is supported by a Grant from ARC. Inderbir Gill is a paid consultant for Hansen Medical and EDAP. Osamu Ukimura is an Advisory Board Member of SonaCare Medical LLC. All others have nothing to disclose.. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 912-923.	0.8	46
59	High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity. <i>Radiotherapy and Oncology</i> , 2014, 110, 268-271.	0.3	66

#	ARTICLE	IF	CITATIONS
60	Impact of national guidelines on brachytherapy monotherapy practice patterns for prostate cancer. <i>Cancer</i> , 2014, 120, 824-832.	2.0	4
61	Brachytherapy Physics. , 2014, , 315-381.		2
62	Introduction of Transperineal Image-Guided Prostate Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 907-915.	0.4	3
63	In regards to Da Silva Franca et al.: "Localized prostate cancer with intermediate- or high-risk features treated with combined external beam radiotherapy and iodine-125 seed brachytherapy" (Brachytherapy) <i>Tj ETQq1o1z0.7843d4 rgBT</i>		
64	Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. <i>Brachytherapy</i> , 2014, 13, 456-464.	0.2	6
65	Shape analysis of the prostate: Establishing imaging specifications for the design of a transurethral imaging device for prostate brachytherapy guidance. <i>Brachytherapy</i> , 2014, 13, 465-470.	0.2	2
66	Recent developments and best practice in brachytherapy treatment planning. <i>British Journal of Radiology</i> , 2014, 87, 20140146.	1.0	23
67	Comparison of biochemical failure rates between permanent prostate brachytherapy and radical retropubic prostatectomy as a function of posttherapy PSA nadir plus $\hat{\alpha}^{\infty}X^{\hat{\alpha}^{\infty}}$. <i>Radiation Oncology</i> , 2014, 9, 171.	1.2	5
68	Long-term outcome of early stage prostate cancer treated with brachytherapy analysis after a mean follow-up of 7 years. <i>SpringerPlus</i> , 2014, 3, 357.	1.2	2
69	Dose to the Bladder Neck Is the Most Important Predictor for Acute and Late Toxicity After Low-Dose-Rate Prostate Brachytherapy: Implications for Establishing New Dose Constraints for Treatment Planning. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 312-319.	0.4	78
70	Establishing High-Quality Prostate Brachytherapy Using a Phantom Simulator Training Program. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 579-586.	0.4	43
71	Evaluation of time, attendance of medical staff, and resources during interstitial brachytherapy for prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 358-363.	1.0	3
72	Patterns of failure after iodine-125 seed implantation for prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 68-71.	0.3	4
73	Light In and Sound Out: Emerging Translational Strategies for Photoacoustic Imaging. <i>Cancer Research</i> , 2014, 74, 979-1004.	0.4	390
74	Dosimetric influence of seed spacers and end-weld thickness for permanent prostate brachytherapy. <i>Brachytherapy</i> , 2014, 13, 304-310.	0.2	8
75	Rebuttal to Drs Stone and Stock. <i>Brachytherapy</i> , 2014, 13, 44-45.	0.2	6
76	Response to Drs Patil and D'Souza. <i>Brachytherapy</i> , 2014, 13, 527-528.	0.2	0
77	Outcomes of T3a Prostate Cancer with Unfavorable Prognostic Factors Treated with Brachytherapy Combined with External Radiotherapy and Hormone Therapy. <i>Chinese Medical Sciences Journal</i> , 2015, 30, 143-149.	0.2	1

#	ARTICLE	IF	CITATIONS
78	Brachytherapy: state-of-the-art radiotherapy in prostate cancer. <i>BJU International</i> , 2015, 116, 80-88.	1.3	20
79	Influence of source batch SK dispersion on dosimetry for prostate cancer treatment with permanent implants. <i>Medical Physics</i> , 2015, 42, 4933-4940.	1.6	1
80	A novel greedy heuristic-based approach to intraoperative planning for permanent prostate brachytherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2015, 16, 229-245.	0.8	2
81	Three-dimensional verification of 125I seed stability after permanent implantation in the parotid gland and periparotid region. <i>Radiation Oncology</i> , 2015, 10, 242.	1.2	3
82	Comparison of permanent 125 I seeds implants with two different techniques in 500 cases of prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2015, 4, 258-264.	0.4	15
83	Reduced dose to urethra and rectum with the use of variable needle spacing in prostate brachytherapy: a potential role for robotic technology. <i>Journal of Contemporary Brachytherapy</i> , 2015, 4, 252-257.	0.4	2
84	Performance and suitability assessment of a real-time 3D electromagnetic needle tracking system for interstitial brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2015, 4, 280-289.	0.4	32
85	Safety and efficacy of salvage low-dose-rate brachytherapy for prostate bed recurrences following radical prostatectomy. <i>Journal of Contemporary Brachytherapy</i> , 2015, 4, 241-246.	0.4	10
86	Difference in the rate of rectal complications following prostate brachytherapy based on the prostate-rectum distance and the prostate longitudinal length among early prostate cancer patients. <i>Korean Journal of Urology</i> , 2015, 56, 637.	1.2	11
87	Review of advanced catheter technologies in radiation oncology brachytherapy procedures. <i>Cancer Management and Research</i> , 2015, 7, 199.	0.9	23
88	High Intensity Focused Ultrasound versus Brachytherapy for the Treatment of Localized Prostate Cancer: A Matched-Pair Analysis. <i>Advances in Urology</i> , 2015, 2015, 1-9.	0.6	10
89	Original paper Evaluation of the dosimetric impact of loss and displacement of seeds in prostate low-dose-rate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2015, 3, 203-210.	0.4	17
90	Clinical implications of a prostate-specific antigen bounce after radiation therapy for prostate cancer. <i>International Journal of Clinical Oncology</i> , 2015, 20, 598-604.	1.0	15
91	A Comparison of US- Versus MR-Based 3-D Prostate Shapes Using Radial Basis Function Interpolation and Statistical Shape Models. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2015, 19, 623-634.	3.9	5
92	Whole Pelvis Versus Prostate-Only Radiotherapy With or Without Short-Course Androgen Deprivation Therapy and Mortality Risk. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 555-561.	0.9	5
93	Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints. <i>Radiotherapy and Oncology</i> , 2015, 117, 262-269.	0.3	22
94	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2015, 14, 511-516.	0.2	4
95	Implanted brachytherapy seed movement reflecting transrectal ultrasound probe-induced prostate deformation. <i>Brachytherapy</i> , 2015, 14, 809-817.	0.2	7

#	ARTICLE	IF	CITATIONS
96	Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients. <i>Brachytherapy</i> , 2015, 14, 111-117.	0.2	41
97	Permanent prostate brachytherapy and short-term androgen deprivation for intermediate-risk prostate cancer in Japanese men: Outcome and toxicity. <i>Brachytherapy</i> , 2015, 14, 118-123.	0.2	8
98	Dosimetric evaluation of clinical target volume in the postimplant analysis of low-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2015, 14, 189-196.	0.2	9
99	Technical Aspects of Focal Therapy in Localized Prostate Cancer. , 2015, , .		10
100	Permanent seed brachytherapy for clinically localized prostate cancer: Long-term outcomes in a 700 patient cohort. <i>Brachytherapy</i> , 2015, 14, 166-172.	0.2	17
101	The Royal College of Radiologists' Audit of Prostate Brachytherapy in the Year 2012. <i>Clinical Oncology</i> , 2015, 27, 330-336.	0.6	8
102	Measurement uncertainty analysis of low-dose-rate prostate seed brachytherapy: post-implant dosimetry. <i>Australasian Physical and Engineering Sciences in Medicine</i> , 2015, 38, 71-81.	1.4	6
103	Comparing CTVs for permanent prostate brachytherapy. <i>Clinical and Translational Oncology</i> , 2015, 17, 393-397.	1.2	0
104	Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. <i>Brachytherapy</i> , 2015, 14, 316-321.	0.2	8
105	Regional dose metrics as predictors of biochemical failure and local recurrence after low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2015, 14, 350-358.	0.2	5
106	An open-source genetic algorithm for determining optimal seed distributions for low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2015, 14, 692-702.	0.2	6
107	Refining prostate seed brachytherapy: Comparing high-, intermediate-, and low-activity seeds for I-125 permanent seed prostate brachytherapy. <i>Brachytherapy</i> , 2015, 14, 329-333.	0.2	6
108	Optimised Robust Treatment Plans for Prostate Cancer Focal Brachytherapy. <i>Procedia Computer Science</i> , 2015, 51, 914-923.	1.2	15
109	Calcifications in low-dose rate prostate seed brachytherapy treatment: Post-planning dosimetry and predictive factors. <i>Radiotherapy and Oncology</i> , 2015, 114, 339-344.	0.3	18
110	Safety and efficacy of iodine-125 permanent prostate brachytherapy in patients with J-pouch anastomosis after total colectomy for ulcerative colitis. <i>Practical Radiation Oncology</i> , 2015, 5, e437-e442.	1.1	16
111	Brachytherapy in pelvic malignancies: a review for radiologists. <i>Abdominal Imaging</i> , 2015, 40, 2645-2659.	2.0	2
112	Development of virtual patient models for permanent implant brachytherapy Monte Carlo dose calculations: interdependence of CT image artifact mitigation and tissue assignment. <i>Physics in Medicine and Biology</i> , 2015, 60, 6039-6062.	1.6	7
113	Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer. <i>Brachytherapy</i> , 2015, 14, 818-825.	0.2	11

#	ARTICLE	IF	CITATIONS
114	Development of a brachytherapy audit checklist tool. <i>Brachytherapy</i> , 2015, 14, 963-969.	0.2	4
115	<scp>E</scp>psteinâ€< scp>B</scp>arr virusâ€induced polyclonal lymphoproliferative disorder of lymphoplasmacytic type in an autopsy case of aplastic anemia treated twice with antiâ€thymocyte globulin therapy. <i>Pathology International</i> , 2015, 65, 274-276.	0.6	3
116	A simple analytical method for heterogeneity corrections in low dose rate prostate brachytherapy. <i>Physics in Medicine and Biology</i> , 2015, 60, 5455-5469.	1.6	3
117	Radiotherapy in Prostate Cancer. <i>Medical Radiology</i> , 2015, , .	0.0	6
118	Permanent interstitial low-dose-rate brachytherapy for patients with low risk prostate cancer. <i>Strahlentherapie Und Onkologie</i> , 2015, 191, 303-309.	1.0	13
119	Combination of androgen deprivation therapy and radiotherapy for localized prostate cancer in the contemporary era. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 93, 136-148.	2.0	6
121	Resource Documents. , 2016, , 327-349.		0
122	Prostate Seed Implant. , 2016, , 287-304.		0
123	The impact of body mass index on dosimetric quality in low-dose-rate prostate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2016, 5, 386-390.	0.4	0
124	Predictors of prostate volume reduction following neoadjuvant cytoreductive androgen suppression. <i>Journal of Contemporary Brachytherapy</i> , 2016, 5, 371-378.	0.4	5
125	Dosimetry of permanent interstitial prostate brachytherapy for an interoperative procedure, using O-arm based CT and TRUS. <i>Journal of Contemporary Brachytherapy</i> , 2016, 1, 7-16.	0.4	15
126	Which patients benefit from postâ€implant <scp>CT</scp> dosimetry after realâ€time intraoperative planning for <scp>LDR</scp> prostate brachytherapy: Should intraoperatively planned patients be treated differently?. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2016, 60, 244-246.	0.9	1
127	Prostate deformation from inflatable rectal probe cover and dosimetric effects in prostate seed implant brachytherapy. <i>Medical Physics</i> , 2016, 43, 6569-6576.	1.6	0
128	Trends in targeted prostate brachytherapy: from multiparametric MRI to nanomolecular radiosensitizers. <i>Cancer Nanotechnology</i> , 2016, 7, 6.	1.9	9
129	BrachyView: multiple seed position reconstruction and comparison with CT post-implant dosimetry. <i>Journal of Instrumentation</i> , 2016, 11, P05002-P05002.	0.5	4
130	Comparative study of late rectal toxicity in prostate cancer patients treated with low-dose-rate brachytherapy: With or without supplemental external beam radiotherapy. <i>Brachytherapy</i> , 2016, 15, 435-441.	0.2	19
131	The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2016, 15, 156-162.	0.2	3
132	Re: Transperineal Template Guided Prostate Biopsy Selects Candidates for Active Surveillanceâ€”How Many Cores are Enough?. <i>Journal of Urology</i> , 2016, 195, 1624-1625.	0.2	0

#	ARTICLE	IF	CITATIONS
133	A radiobiology-based inverse treatment planning method for optimisation of permanent I-125 prostate implants in focal brachytherapy. <i>Physics in Medicine and Biology</i> , 2016, 61, 430-444.	1.6	16
134	Rectal dose constraints for salvage iodine-125 prostate brachytherapy. <i>Brachytherapy</i> , 2016, 15, 85-93.	0.2	23
136	Sensitivity of clinically relevant dosimetric parameters to contouring uncertainty in postimplant dosimetry of low-dose-rate prostate permanent seed brachytherapy. <i>Brachytherapy</i> , 2016, 15, 774-779.	0.2	8
137	Stranded seed displacement, migration, and loss after permanent prostate brachytherapy as estimated by Day 0 fluoroscopy and 4-month postimplant pelvic x-ray. <i>Brachytherapy</i> , 2016, 15, 714-721.	0.2	11
138	Assessment of the feasibility of using transrectal ultrasound for postimplant dosimetry in low-dose-rate prostate brachytherapy. <i>Medical Dosimetry</i> , 2016, 41, 290-295.	0.4	4
139	Race and mortality risk after radiation therapy in men treated with or without androgen suppression therapy for favorable-risk prostate cancer. <i>Cancer</i> , 2016, 122, 3608-3614.	2.0	16
141	Técnicas de braquiterapia por câncer de próstata. <i>EMC - Urologia</i> , 2016, 48, 1-13.	0.0	0
142	Optical fibre sensors: their role in in vivo dosimetry for prostate cancer radiotherapy. <i>Cancer Nanotechnology</i> , 2016, 7, 7.	1.9	10
143	Needle Tracking and Deflection Prediction for Robot-Assisted Needle Insertion Using 2D Ultrasound Images. <i>Journal of Medical Robotics Research</i> , 2016, 01, 1640001.	1.0	18
144	Radiation safety of receptive anal intercourse with prostate cancer patients treated with low-dose-rate brachytherapy. <i>Brachytherapy</i> , 2016, 15, 420-425.	0.2	7
145	Robustness to source displacement in dual air kerma strength planning for focal low-dose-rate brachytherapy of prostate cancer. <i>Brachytherapy</i> , 2016, 15, 642-649.	0.2	3
146	Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. <i>Cancer Treatment Reviews</i> , 2016, 48, 50-60.	3.4	53
147	DNA-PKcs Expression Is a Predictor of Biochemical Recurrence After Permanent Iodine 125 Interstitial Brachytherapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 965-972.	0.4	11
148	Edema and Seed Displacements Affect Intraoperative Permanent Prostate Brachytherapy Dosimetry. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 197-205.	0.4	22
149	A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study. <i>Radiotherapy and Oncology</i> , 2016, 118, 122-130.	0.3	39
150	Three-Dimensional Needle Shape Estimation in TRUS-Guided Prostate Brachytherapy Using 2-D Ultrasound Images. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1621-1631.	3.9	18
151	Randomized non-inferiority trial of Bicalutamide and Dutasteride versus LHRH agonists for prostate volume reduction prior to I-125 permanent implant brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 141-147.	0.3	16
152	Brachytherapy for Prostate Cancer: An Overview. , 2016, , 399-411.		0

#	ARTICLE	IF	CITATIONS
153	Survival outcomes of combined external beam radiotherapy and brachytherapy vs. brachytherapy alone for intermediate-risk prostate cancer patients using the National Cancer Data Base. Brachytherapy, 2016, 15, 136-146.	0.2	8
154	Multiactuator Haptic Feedback on the Wrist for Needle Steering Guidance in Brachytherapy. IEEE Robotics and Automation Letters, 2016, 1, 852-859.	3.3	34
155	Outcomes for prostate glands >60Åcc treated with low-dose-rate brachytherapy. Brachytherapy, 2016, 15, 163-168.	0.2	5
156	Interventional Urology. , 2016, , .		4
157	Brachytherapy. , 2016, , 276-293.e5.		1
159	Association between long-term erectile dysfunction and biochemical recurrence after permanent seed I125implant brachytherapy for prostate cancer. A longitudinal study of a single-institution. Aging Male, 2016, 19, 15-19.	0.9	5
160	Permanent and High Dose Rate Brachytherapy (Technique, Indications, Results, Morbidity). , 2017, , 187-202.		1
161	Low-Dose-Rate Brachytherapy Versus Cryotherapy in Low- and Intermediate-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 101-107.	0.4	11
162	Management of Prostate Cancer. , 2017, , .		5
163	Salvage Prostate Brachytherapy for Postradiation Local Failure. , 2017, , 287-302.		1
164	Prostate magnetic resonance imaging for brachytherapists: Diagnosis, imaging pitfalls, and post-therapy assessment. Brachytherapy, 2017, 16, 688-697.	0.2	17
165	Quantifying 125 I placement accuracy in prostate brachytherapy using postimplant transrectal ultrasound images. Brachytherapy, 2017, 16, 306-312.	0.2	5
166	Cone-beam CT-based adaptive planning improves permanent prostate brachytherapy dosimetry: An analysis of 1266 patients. Medical Physics, 2017, 44, 1257-1267.	1.6	9
167	Permanent prostate brachytherapy pubic arch evaluation with diagnostic magnetic resonance imaging. Brachytherapy, 2017, 16, 728-733.	0.2	4
168	Magnetic resonance imaging in prostate brachytherapy: Evidence, clinical end points to data, and direction forward. Brachytherapy, 2017, 16, 659-664.	0.2	7
169	American Brachytherapy Society Task Group Report: Use of androgen deprivation therapy with prostate brachytherapyâ€”A systematic literature review. Brachytherapy, 2017, 16, 245-265.	0.2	46
170	Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow. Brachytherapy, 2017, 16, 734-742.	0.2	29
171	Magnetic resonance imaging basics for the prostate brachytherapist. Brachytherapy, 2017, 16, 715-727.	0.2	17

#	ARTICLE	IF	CITATIONS
172	Image Guidance Systems for Brachytherapy. , 2017, , 69-98.		0
173	Oncological and functional results of robotic salvage radical prostatectomy after permanent brachytherapy implants. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2017, 21, 119-123.	0.6	8
175	Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers. Brachytherapy, 2017, 16, 761-769.	0.2	9
176	Brachytherapy in the Management of Prostate Cancer. Surgical Oncology Clinics of North America, 2017, 26, 491-513.	0.6	17
177	Towards clinical application of RayStretch for heterogeneity corrections in LDR permanent 125 I prostate brachytherapy. Brachytherapy, 2017, 16, 616-623.	0.2	1
178	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.4	9
180	Dosimetric comparison between treatment plans of patients treated with low-dose-rate vs. high-dose-rate interstitial prostate brachytherapy as monotherapy: Initial findings of a randomized clinical trial. Brachytherapy, 2017, 16, 608-615.	0.2	29
181	Issues in closed-loop needle steering. Control Engineering Practice, 2017, 62, 55-69.	3.2	78
182	ACR appropriateness criteria: Permanent source brachytherapy for prostate cancer. Brachytherapy, 2017, 16, 266-276.	0.2	26
183	Recent Developments in Radiotherapy. New England Journal of Medicine, 2017, 377, 1065-1075.	13.9	313
184	Variability of treatment planning of seed implantation: A Japanese multicenter simulation study. Brachytherapy, 2017, 16, 1013-1020.	0.2	1
185	Prostate cancer focal brachytherapy: Improving treatment plan robustness using a convolved dose rate model. Procedia Computer Science, 2017, 108, 1522-1531.	1.2	2
187	Can the Day 0 CT-scan predict the post-implant scanning? Results from 136 prostate cancer patients. Physica Medica, 2017, 40, 66-71.	0.4	0
188	Performance of a palladium-103 line source for prostate brachytherapy implants: A Phase I trial. Brachytherapy, 2017, 16, 1007-1012.	0.2	3
189	The evolution of brachytherapy for prostate cancer. Nature Reviews Urology, 2017, 14, 415-439.	1.9	106
190	American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. Brachytherapy, 2017, 16, 1-12.	0.2	69
191	Large-scale Retrospective Monte Carlo Dosimetric Study for Permanent Implant Prostate Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2017, 97, 606-615.	0.4	18
192	Advances in Prostate Cancer Magnetic Resonance Imaging and Positron Emission Tomography-Computed Tomography for Staging and Radiotherapy Treatment Planning. Seminars in Radiation Oncology, 2017, 27, 21-33.	1.0	24

#	ARTICLE	IF	CITATIONS
193	Hydrogel spacers in prostate radiotherapy: a promising approach to decrease rectal toxicity. <i>Future Oncology</i> , 2017, 13, 2697-2708.	1.1	8
194	Stenting of the Portal Vein Combined with Different Numbers of Iodine-125 Seed Strands. <i>Chinese Medical Journal</i> , 2017, 130, 2183-2189.	0.9	7
195	Prostate-Specific Antigen 5 Years following Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: An Ablative Procedure?. <i>Frontiers in Oncology</i> , 2017, 7, 157.	1.3	15
196	Focal therapy for prostate cancer: the technical challenges. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 383-389.	0.4	10
197	Current status of brachytherapy in cancer treatment – short overview. <i>Journal of Contemporary Brachytherapy</i> , 2017, 9, 581-589.	0.4	117
198	The use of trans-applicator intracavitary ultrasonography in brachytherapy for cervical cancer: phantom study of a novel approach to 3D image-guided brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2017, 2, 151-157.	0.4	3
199	Comparison of prostate contours between conventional stepping transverse imaging and Twister-based sagittal imaging in permanent interstitial prostate brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2017, 4, 316-322.	0.4	0
200	Brachytherapy: The Original Altered Fractionation. <i>Medical Radiology</i> , 2017, , 65-73.	0.0	0
201	Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2018, 17, 517-523.	0.2	9
202	Time-driven activity-based cost comparison of prostate cancer brachytherapy and intensity-modulated radiation therapy. <i>Brachytherapy</i> , 2018, 17, 556-563.	0.2	38
203	IDEAL 2a Phase II Study of Ultrafocal Brachytherapy for Low- and Intermediate-risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 903-911.	0.4	19
204	EM-enhanced US-based seed detection for prostate brachytherapy. <i>Medical Physics</i> , 2018, 45, 2357-2368.	1.6	8
205	Initial clinical assessment of –center-specific– automated treatment plans for low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2018, 17, 476-488.	0.2	3
206	Manual vs. automated implantation of seeds in prostate brachytherapy: Oncologic results from a single-center study. <i>Brachytherapy</i> , 2018, 17, 214-220.	0.2	3
207	Comparison of prostate distortion by inflatable and rigid endorectal MRI coils in permanent prostate brachytherapy imaging. <i>Brachytherapy</i> , 2018, 17, 298-305.	0.2	7
208	Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. <i>BJU International</i> , 2018, 121, 774-780.	1.3	12
209	<scp>COMP</scp> report: <scp>CPQR</scp> technical quality control guidelines for low-dose-rate permanent seed brachytherapy. <i>Journal of Applied Clinical Medical Physics</i> , 2018, 19, 13-18.	0.8	0
210	Long-term oncological outcomes and toxicity in 597 men aged ≥60 years at time of low-dose-rate brachytherapy for localised prostate cancer. <i>BJU International</i> , 2018, 121, 38-45.	1.3	27

#	ARTICLE	IF	CITATIONS
211	Late seed migration after prostate brachytherapy with Iod-125 permanent implants. Prostate International, 2018, 6, 66-70.	1.2	10
212	Use of 5-alpha-reductase inhibitors as alternatives to luteinizing-hormone releasing hormone (LHRH) analogs or anti-androgens for prostate downsizing before brachytherapy. Practical Radiation Oncology, 2018, 8, e159-e165.	1.1	1
213	Proof of Principle for Local Delivery of a c-Met Inhibitor. Journal of Pharmaceutical Sciences, 2018, 107, 856-862.	1.6	0
214	Brachytherapy patient safety events in an academic radiation medicine program. Brachytherapy, 2018, 17, 16-23.	0.2	13
215	Contemporary Radiation Treatment of Prostate Cancer in Africa: A Ghanaian Experience. Journal of Global Oncology, 2018, 4, 1-13.	0.5	8
216	The role of salvage brachytherapy for local relapse after external beam radiotherapy for prostate cancer. Translational Andrology and Urology, 2018, 7, 414-435.	0.6	16
218	Predicting pubic arch interference in permanent prostate brachytherapy based on the specific parameters derived from nuclear magnetic resonance imaging. Journal of Contemporary Brachytherapy, 2018, 10, 405-410.	0.4	3
219	Acute and late toxicities in localized prostate cancer patients treated with low-dose 125I brachytherapy (110 Gy) in combination with external beam radiation therapy versus brachytherapy alone (160 Gy). Journal of Contemporary Brachytherapy, 2018, 10, 397-404.	0.4	3
221	EXPERIMENTAL STUDY OF NEEDLE INSERTION STRATEGIES OF SEED IMPLANTATION ARTICULATED ROBOT. Journal of Mechanics in Medicine and Biology, 2018, 18, 1850023.	0.3	5
223	Five-year effectiveness of low-dose-rate brachytherapy: comparisons with nomogram predictions in patients with non-metastatic prostate cancer presenting significant control of intra- and periprostatic disease. Journal of Contemporary Brachytherapy, 2018, 10, 297-305.	0.4	12
224	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2018, , 1-16.		0
225	Inferring postimplant dose distribution of salvage permanent prostate implant (PPI) after primary PPI on CT images. Brachytherapy, 2018, 17, 866-873.	0.2	8
226	Contemporary prostate cancer radiation therapy in the United States: Patterns of care and compliance with quality measures. Practical Radiation Oncology, 2018, 8, 307-316.	1.1	12
227	A cold spot compensation technique using a combination of trans-rectal ultrasonography and intraoperative computed tomography for interstitial permanent prostate brachytherapy: a single-arm prospective trial. Journal of Contemporary Brachytherapy, 2018, 10, 10-16.	0.4	0
229	Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer. Cancer, 2018, 124, 3528-3535.	2.0	15
230	A process to describe radiation damage at the molecular level. Application to the 125I seeds in water. Applied Radiation and Isotopes, 2018, 140, 163-170.	0.7	1
231	Predictive factors of long-term rectal toxicity following permanent iodine-125 prostate brachytherapy with or without supplemental external beam radiation therapy in 2216 patients. Brachytherapy, 2018, 17, 799-807.	0.2	9
232	Low dose rate prostate brachytherapy. Translational Andrology and Urology, 2018, 7, 341-356.	0.6	30

#	ARTICLE	IF	CITATIONS
233	Time to PSA rise differentiates the PSA bounce after HDR and LDR brachytherapy of prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 1-9.	0.4	9
234	Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer. <i>World Journal of Surgical Oncology</i> , 2018, 16, 107.	0.8	4
235	UK & Ireland Prostate Brachytherapy Practice Survey 2014-2016. <i>Journal of Contemporary Brachytherapy</i> , 2018, 10, 238-245.	0.4	7
236	Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 116-126.	0.4	11
237	Permanent seed implant brachytherapy in low-risk prostate cancer: Preoperative planning with 145 Gy versus real-time intraoperative planning with 160 Gy. <i>Reports of Practical Oncology and Radiotherapy</i> , 2018, 23, 290-297.	0.3	5
238	Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database. <i>Advances in Radiation Oncology</i> , 2018, 3, 170-180.	0.6	47
239	A Phase 2 Randomized Pilot Study Comparing High-Dose-Rate Brachytherapy and Low-Dose-Rate Brachytherapy as Monotherapy in Localized Prostate Cancer. <i>Advances in Radiation Oncology</i> , 2019, 4, 631-640.	0.6	21
240	Radiation-related Adverse Effects of CT-guided Implantation of 125I Seeds for Thoracic Recurrent and/or Metastatic Malignancy. <i>Scientific Reports</i> , 2019, 9, 14803.	1.6	5
241	Dosimetric and radiobiological investigation of permanent implant prostate brachytherapy based on Monte Carlo calculations. <i>Brachytherapy</i> , 2019, 18, 875-882.	0.2	1
242	Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Urology. <i>BJU International</i> , 2019, 124, 221-241.	1.3	4
243	Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning. <i>Brachytherapy</i> , 2019, 18, 338-347.	0.2	1
244	Combined-modality 125I-seed-brachytherapy, external beam radiation and androgen deprivation therapy of unfavorable-risk prostate cancer: report of outcomes and side-effects. <i>World Journal of Urology</i> , 2019, 37, 2355-2363.	1.2	4
245	Interobserver variability of 3.0-tesla and 1.5-tesla magnetic resonance imaging/computed tomography fusion image-based post-implant dosimetry of prostate brachytherapy. <i>Journal of Radiation Research</i> , 2019, 60, 483-489.	0.8	2
246	Deformable registration of x ray and MRI for postimplant dosimetry in low dose rate prostate brachytherapy. <i>Medical Physics</i> , 2019, 46, 3961-3973.	1.6	0
247	Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid. <i>Contrast Media and Molecular Imaging</i> , 2019, 2019, 1-9.	0.4	11
248	High-dose-rate brachytherapy as monotherapy for prostate cancer: The impact of cellular repair and source decay. <i>Brachytherapy</i> , 2019, 18, 701-710.	0.2	9
249	The current state of randomized clinical trial evidence for prostate brachytherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 599-610.	0.8	8
250	Comparison of multiparametric MRI-based and transrectal ultrasound-based preplans with intraoperative ultrasound-based planning for low dose rate interstitial prostate seed implantation. <i>Journal of Applied Clinical Medical Physics</i> , 2019, 20, 31-38.	0.8	6

#	ARTICLE	IF	CITATIONS
251	Deep Attentive Features for Prostate Segmentation in 3D Transrectal Ultrasound. IEEE Transactions on Medical Imaging, 2019, 38, 2768-2778.	5.4	126
252	Transitioning From a Low-Dose-Rate to a High-Dose-Rate Prostate Brachytherapy Program: Comparing Initial Dosimetry and Improving Workflow Efficiency Through Targeted Interventions. Advances in Radiation Oncology, 2019, 4, 103-111.	0.6	6
253	Reducing seed migration to near zero with stranded-seed implants: Comparison of seed migration rates to the chest in 1000 permanent prostate brachytherapy patients undergoing implants with loose or stranded seeds. Brachytherapy, 2019, 18, 306-312.	0.2	12
254	Permanent prostate brachytherapy is safe in men with severe baseline lower urinary tract symptoms. Brachytherapy, 2019, 18, 332-337.	0.2	1
255	Prostate brachytherapy procedural training: incorporation of related procedures in resident training and competency assessment. Journal of Contemporary Brachytherapy, 2019, 11, 601-606.	0.4	3
256	The development of high quality training program for real time trans rectal ultrasound low dose rate (LDR) prostate brachytherapy. Physica Medica, 2019, 67, 200.	0.4	0
257	High-dose-rate prostate brachytherapy appears safe in patients with high baseline International Prostate Symptom Scores. Brachytherapy, 2019, 18, 793-799.	0.2	8
258	Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer. Journal of Contemporary Brachytherapy, 2019, 11, 409-416.	0.4	5
259	Feasibility of an MRI-only workflow for postimplant dosimetry of low-dose-rate prostate brachytherapy: Transition from phantoms to patients. Brachytherapy, 2019, 18, 863-874.	0.2	7
260	Modern Brachytherapy. Hematology/Oncology Clinics of North America, 2019, 33, 1011-1025.	0.9	14
261	Evaluation of the accuracy of computer-assisted techniques in the interstitial brachytherapy of the deep regions of the head and neck. Brachytherapy, 2019, 18, 217-223.	0.2	9
262	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2019, , 1-16.		0
263	Patient-reported health-related quality of life outcomes after HDR brachytherapy between small ($\leq 60\text{Åcc}$) and large ($\geq 60\text{Åcc}$) prostate glands. Brachytherapy, 2019, 18, 13-21.	0.2	7
264	Permanent prostate brachytherapy monotherapy with I-125 for low- and intermediate-risk prostate cancer: Outcomes in 974 patients. Brachytherapy, 2019, 18, 1-7.	0.2	19
265	Risk of Pelvic Fracture With Radiation Therapy in Older Patients. International Journal of Radiation Oncology Biology Physics, 2020, 106, 485-492.	0.4	23
266	Efficacy and safety of CT-guided 125I seed implantation as a salvage treatment for locally recurrent head and neck soft tissue sarcoma after surgery and external beam radiotherapy: A 12-year study at a single institution. Brachytherapy, 2020, 19, 81-89.	0.2	26
267	Comparison of outcome endpoints in intermediate- and high-risk prostate cancer after combined-modality radiotherapy. Brachytherapy, 2020, 19, 24-32.	0.2	4
268	Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. International Journal of Urology, 2020, 27, 17-23.	0.5	17

#	ARTICLE	IF	CITATIONS
269	Tumor burden and location as prognostic factors in patients treated by iodine seed implant brachytherapy for localized prostate cancers. <i>Radiation Oncology</i> , 2020, 15, 1.	1.2	31
270	Postimplant Dosimetry of Permanent Prostate Brachytherapy: Comparison of MRI-Only and CT-MRI Fusion-Based Workflows. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 206-215.	0.4	13
271	Practical Radiation Oncology. , 2020, , .		5
272	Relationship between radiation doses and erectile function deterioration in patients with localized prostate cancer treated with permanent prostate brachytherapy. <i>International Journal of Urology</i> , 2020, 27, 1087-1093.	0.5	3
273	Development and Validation of a Genomic Tool to Predict Seminal Vesicle Invasion in Adenocarcinoma of the Prostate. <i>JCO Precision Oncology</i> , 2020, 4, 1228-1238.	1.5	2
274	Brachytherapy in Belgium in 2018. A national survey of the brachytherapy study group of the Belgian Society for Radiotherapy and Oncology (BeSTRO). <i>Radiotherapy and Oncology</i> , 2020, 150, 245-252.	0.3	5
275	Impact of real-time, dose-escalated permanent seed implant brachytherapy in intermediate-risk prostate cancer. <i>Reports of Practical Oncology and Radiotherapy</i> , 2020, 25, 463-469.	0.3	3
276	The accuracy and safety of CT-guided iodine-125 seed implantation assisted by 3D non-coplanar template for retroperitoneal recurrent carcinoma. <i>World Journal of Surgical Oncology</i> , 2020, 18, 307.	0.8	7
277	A deep learning method for real-time intraoperative US image segmentation in prostate brachytherapy. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020, 15, 1467-1476.	1.7	22
278	Diagnostic performance of imaging techniques for detecting of local recurrence after prostate brachytherapy. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2020, 24, 323-331.	0.6	1
279	A-blockers for the management of lower urinary tract symptoms in patients with prostate cancer treated with external beam radiotherapy: a randomized controlled study. <i>World Journal of Urology</i> , 2021, 39, 1805-1813.	1.2	5
280	I-125 or Pd-103 for brachytherapy boost in men with high-risk prostate cancer: A comparison of survival and morbidity outcomes. <i>Brachytherapy</i> , 2020, 19, 567-573.	0.2	1
281	Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 469-476.	0.6	2
282	Low dose rate permanent seed brachytherapy: tracing its evolution and current status. <i>Precision Radiation Oncology</i> , 2020, 4, 89-98.	0.4	2
283	Evaluation of transrectal ultrasound-based dosimetry for brachytherapy of prostate cancer: a single-center experience. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 327-334.	0.4	0
284	A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 1-5.	0.4	7
285	Dosimetry, efficacy, and safety of three-dimensional printing noncoplanar template-assisted and CT-guided 125I seed implantation for recurrent retroperitoneal lymphatic metastasis after external beam radiotherapy. <i>Brachytherapy</i> , 2020, 19, 380-388.	0.2	11
286	Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer in Men With a High Baseline International Prostate Symptom Score (IPSS ≥ 15). <i>Frontiers in Oncology</i> , 2020, 10, 1060.	1.3	7

#	ARTICLE	IF	CITATIONS
287	Long-term oncological and functional follow-up in low-dose-rate brachytherapy for prostate cancer: results from the prospective nationwide Swiss registry. <i>BJU International</i> , 2020, 125, 827-835.	1.3	7
288	Oligorecurrence Non-small Cell Lung Cancer After Failure of First-Line Chemotherapy: Computed Tomography-Guided 125I Seed Implantation vs. Second-Line Chemotherapy. <i>Frontiers in Oncology</i> , 2020, 10, 470.	1.3	12
289	Salvage Therapy for Prostate Cancer. , 2021, , .		0
290	Accuracy and dosimetric parameters comparison of 3D-printed non-coplanar template-assisted computed tomography-guided iodine-125 seed ablative brachytherapy in pelvic lateral recurrence of gynecological carcinomas. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 39-45.	0.4	10
291	Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e15.	1.0	18
292	Characterization and registration of 3D ultrasound for use in permanent breast seed implant brachytherapy treatment planning. <i>Brachytherapy</i> , 2021, 20, 248-256.	0.2	3
293	Eligibility criteria according to EAU/ESTRO/SIOG guidelines for exclusive iodine-125 brachytherapy for intermediate-risk prostate adenocarcinoma patients: impact on relapse-free survival. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 373-386.	0.4	2
294	Analysis of radioactive implant migration in patients treated with iodine-125 seeds for permanent prostate brachytherapy with MRI-classified median lobe hyperplasia. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 254-262.	0.4	2
295	Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. <i>Cancer</i> , 2021, 127, 1912-1925.	2.0	6
296	Relapse patterns after low-dose-rate prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 291-295.	0.2	4
297	Development and Preliminary Evaluation of an Anthropomorphic Trans-rectal Ultrasound Prostate Brachytherapy Training Phantom. <i>Ultrasound in Medicine and Biology</i> , 2021, 47, 833-846.	0.7	6
298	Localized and Locally Advanced Prostate Cancer: Treatment Options. <i>Oncology</i> , 2021, 99, 1-9.	0.9	12
299	Management of Lower Urinary Tract Symptoms after Prostate Radiation. <i>Current Urology Reports</i> , 2021, 22, 37.	1.0	4
300	Acute and late side-effects after low dose-rate brachytherapy for prostate cancer; incidence, management and technical considerations. <i>Brachytherapy</i> , 2021, 20, 956-965.	0.2	6
301	The one hundred most cited publications in prostate brachytherapy. <i>Brachytherapy</i> , 2021, 20, 611-623.	0.2	1
302	Outcomes with brachytherapy based dose escalation for gleason 8 versus 9-10 prostate cancer: An NCDB analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 829.e19-829.e26.	0.8	2
303	Optical fibre based real-time measurements during an LDR prostate brachytherapy implant simulation: using a 3D printed anthropomorphic phantom. <i>Scientific Reports</i> , 2021, 11, 11160.	1.6	9
304	Brachytherapy: A Comprehensive Review. <i>Progress in Medical Physics</i> , 2021, 32, 25-39.	0.5	5

#	ARTICLE	IF	CITATIONS
305	Learning With Context Feedback Loop for Robust Medical Image Segmentation. IEEE Transactions on Medical Imaging, 2021, 40, 1542-1554.	5.4	30
306	Comparison between postoperative TRUS-CT fusion with MRI-CT fusion for postimplant quality assurance in prostate LDR permanent seed brachytherapy. Brachytherapy, 2021, 20, 849-856.	0.2	2
307	Live implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy. Brachytherapy, 2021, 20, 873-882.	0.2	1
308	Stereotactic Ablative Brachytherapy: Recent Advances in Optimization of Radiobiological Cancer Therapy. Cancers, 2021, 13, 3493.	1.7	6
309	Medium-term oncological and functional outcomes of hemi-gland brachytherapy using iodine-125 seeds for intermediate-risk unilateral prostate cancer. Brachytherapy, 2021, 20, 842-848.	0.2	5
310	Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy. Brachytherapy, 2021, 20, 1139-1145.	0.2	3
311	Focal low dose-rate brachytherapy for low to intermediate risk prostate cancer: preliminary experience at an Australian institution. Translational Andrology and Urology, 2021, 10, 3591-3603.	0.6	7
312	Radioactive Iodine-125 in Tumor Therapy: Advances and Future Directions. Frontiers in Oncology, 2021, 11, 717180.	1.3	19
313	Low dose rate brachytherapy for primary treatment of localized prostate cancer: A systemic review and executive summary of an evidence-based consensus statement. Brachytherapy, 2021, 20, 1114-1129.	0.2	26
314	A Multi-Institutional Phase 2 Trial of High-Dose SAbR for Prostate Cancer Using Rectal Spacer. International Journal of Radiation Oncology Biology Physics, 2021, 111, 101-109.	0.4	19
315	Automatic localization of the prostatic urethra for image guided radiation therapy. Technical Innovations and Patient Support in Radiation Oncology, 2021, 19, 1-6.	0.6	0
316	High Dose Rate Prostate Brachytherapy. Practical Guides in Radiation Oncology, 2021, , 127-151.	0.0	0
317	Prostate Brachytherapy: Low Dose Rate. , 2013, , 719-738.		1
318	Prostate: Low Dose Rate Brachytherapy. Medical Radiology, 2016, , 299-317.	0.0	1
319	Modelling and optimisation of treatment parameters in high-dose-rate mono brachytherapy for localised prostate carcinoma using a multilayer artificial neural network and a genetic algorithm: Pilot study. Computers in Biology and Medicine, 2020, 126, 104045.	3.9	4
320	Rectal ulcer associated with SpaceOAR hydrogel insertion during prostate brachytherapy. BMJ Case Reports, 2014, 2014, bcr2014206931-bcr2014206931.	0.2	31
321	Comparison of pre-implant treatment planning and post-implant dosimetry in I ¹²⁵ spinal metastases brachytherapy. Oncology Letters, 2020, 19, 309-316.	0.8	5
322	Expert consensus on computed tomography-assisted three-dimensional-printed coplanar template guidance for interstitial permanent radioactive ¹²⁵ I seed implantation therapy. Journal of Cancer Research and Therapeutics, 2019, 15, 1430.	0.3	14

#	ARTICLE	IF	CITATIONS
323	Expert consensus statement on computed tomography-guided ¹²⁵ I radioactive seeds permanent interstitial brachytherapy. <i>Journal of Cancer Research and Therapeutics</i> , 2018, 14, 12.	0.3	34
324	Prostate Cancer: Locoregional Disease. UNIPA Springer Series, 2021, , 791-803.	0.1	0
325	Guidelines for radiotherapy of prostate cancer (2020 edition). <i>Precision Radiation Oncology</i> , 2021, 5, 160-182.	0.4	8
326	Dosimetry Planning for Permanent Seeds. , 2013, , 141-147.		0
327	Incidence and Prognostic Factors for Complications After Permanent Interstitial Brachytherapy. , 2013, , 207-213.		0
328	Analysis on the Reporting of Medical Events in Permanent Prostate Brachytherapy. <i>Cureus</i> , 2013, , .	0.2	1
329	Brachytherapy. , 2015, , 79-96.		0
330	Brachytherapy for Prostate Cancer. , 2015, , 743-772.		0
331	Focal Brachytherapy. , 2015, , 153-162.		0
332	A Double Iteration Greedy Heuristic Approach for Permanent Brachytherapy Planning. <i>International Journal of Applied Physics and Mathematics</i> , 2015, 5, 48-59.	0.3	0
334	Image-guided prostate brachytherapy should be MRI-based. <i>Medical Physics</i> , 2016, 43, 6213-6216.	1.6	0
335	Focal Brachytherapy and Intensity-Modulated Radiation Therapy. <i>Current Clinical Urology</i> , 2017, , 355-371.	0.0	0
336	Positioning Focal Therapy from Consensus to Guidelines. <i>Current Clinical Urology</i> , 2017, , 447-463.	0.0	0
337	Brachytherapy guideline in prostate cancer (high and low dose rate). <i>Revista Da Associação Médica Brasileira</i> , 2017, 63, 293-298.	0.3	0
338	Brachytherapy for prostate cancer in light of recent guidelines. <i>Onkologie (Czech Republic)</i> , 2018, 12, 64-67.	0.0	0
339	A Review of Permanent Prostate Brachytherapy as Practiced in Japan. , 2019, , 159-180.		0
340	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2019, , 1-16.		0
342	Radiotherapy for Localized and Locally Advanced Prostate Cancer. , 2019, , 211-226.		0

#	ARTICLE	IF	CITATIONS
343	Application of the transosseous approach for computed tomography-guided radioactive 125-iodine seed implantation for the treatment of thoracic and abdominal lymph node metastases. <i>Journal of Cancer Research and Therapeutics</i> , 2019, 15, 1611.	0.3	1
344	Monte Carlo study on the gold and gadolinium nanoparticles radio-sensitizer effect in the prostate ¹²⁵ I seeds radiotherapy. <i>Polish Journal of Medical Physics and Engineering</i> , 2019, 25, 165-169.	0.2	2
345	Braquiterapia para el c�ncer de pr�stata. Una revisi�n actualizada de su historia, sus indicaciones, la evidencia que la sustenta y sus controversias.. <i>Ars Medica</i> , 2019, 44, 35-43.	0.1	0
346	Prostate Brachytherapy. , 2020, , 121-127.		0
347	High-dose-rate brachytherapy as monotherapy for localized prostate cancer using three different doses �� 14 years of single-centre experience. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 533-539.	0.4	8
348	American Brachytherapy Society radiation oncology alternative payment model task force: Quality measures and metrics for brachytherapy. <i>Brachytherapy</i> , 2022, 21, 63-74.	0.2	3
349	CT-guided palladium-103 seed brachytherapy for metastatic adenoid cystic carcinoma: a retrospective study to assess initial safety and effectiveness of percutaneous CT fluoroscopy-guided permanent seed brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 504-511.	0.4	0
350	BrachyView: Tomographic reconstruction using timepix detectors in post-implant dosimetry checks for permanent prostate brachytherapy implants. , 2013, , .		0
351	Salvage Re-irradiation Therapy After Loco-regional Failure for Radiotherapy. , 2021, , 189-209.		0
352	Combination of 5�-reductase inhibitor with combined androgen blockade (CAB) as a novel cytoreductive regimen before prostate brachytherapy: Ultra-CAB. <i>American Journal of Clinical and Experimental Urology</i> , 2015, 3, 48-50.	0.4	0
354	Impact of hydrogel and hyaluronic acid rectal spacer on rectal dosimetry and toxicity in low-dose-rate prostate brachytherapy: a multi-institutional analysis of patients�� outcomes. <i>Journal of Contemporary Brachytherapy</i> , 2021, 13, 605-614.	0.4	4
355	Longitudinal Changes in Health-related Quality of Life After 125I Low-dose-rate Brachytherapy for Localized Prostate Cancer. <i>Anticancer Research</i> , 2020, 40, 6443-6456.	0.5	5
356	Local seed displacement from Day 0 to Day 30 in I-125 permanent prostate brachytherapy: A detailed, computed tomography-based analysis. <i>Brachytherapy</i> , 2022, 21, 208-215.	0.2	2
357	Prospective Evaluation of Prostate and Organs at Risk Segmentation Software for MRI-based Prostate Radiation Therapy. <i>Radiology: Artificial Intelligence</i> , 2022, 4, e210151.	3.0	7
358	Permanent interstitial brachytherapy for prostate cancer implementing neoadjuvant prostatic artery embolization. <i>Brachytherapy</i> , 2022, 21, 308-316.	0.2	5
359	GEC-ESTRO ACROP prostate brachytherapy guidelines. <i>Radiotherapy and Oncology</i> , 2022, 167, 244-251.	0.3	28
360	Prostate cancer brachytherapy: SFRO guidelines 2021. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2022, 26, 344-355.	0.6	6
361	Case Report: Role of an Iodinated Rectal Hydrogel Spacer, SpaceOAR Vue�,�, in the Context of Low-Dose-Rate Prostate Brachytherapy, for Enhanced Post-Operative Contouring to Aid in Accurate Implant Evaluation and Dosimetry. <i>Frontiers in Oncology</i> , 2021, 11, 810955.	1.3	2

#	ARTICLE	IF	CITATIONS
362	Association between adherence to radiation therapy quality metrics and patient reported outcomes in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, , .	2.0	0
363	Use of a novel anthropomorphic prostate simulator in a prostate brachytherapy transrectal ultrasound imaging workshop for medical physicists. <i>Physica Medica</i> , 2022, 95, 156-166.	0.4	1
364	Outcomes of Patients With Unfavorable Intermediate-Risk Prostate Cancer Treated With External-Beam Radiotherapy Versus Brachytherapy Alone. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 343-350.e4.	2.3	0
365	Axially rigid steerable needle with compliant active tip control. <i>PLoS ONE</i> , 2021, 16, e0261089.	1.1	6
366	Editorial Comment to Triâ€modality therapy with iâ€125 brachytherapy, external beam radiation therapy, and shortâ€term hormone therapy for highâ€risk prostate cancer after holmium laser enucleation of the prostate. <i>IJU Case Reports</i> , 2022, 5, 226-227.	0.1	0
369	Current Status of Radiotherapy Services in Kenya. <i>Journal of Cancer Therapy</i> , 2022, 13, 218-233.	0.1	1
370	ACR-ABS-ASTRO Practice Parameter for Transperineal Permanent Brachytherapy of Prostate Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2022, 45, 249-257.	0.6	1
371	Permanent LDR prostate brachytherapy: Comprehensive characterization of seed-dynamics within the prostate on a seed-only level. <i>Brachytherapy</i> , 2022, 21, 635-646.	0.2	2
372	Learning from the past: a century of accuracy, aspirations, and aspersions in brachytherapy. <i>British Journal of Radiology</i> , 2022, 95, .	1.0	1
373	Mucinous adenocarcinoma of the prostatic urethra after brachytherapy for prostatic adenocarcinoma: a case series. <i>Human Pathology</i> , 2022, 128, 101-109.	1.1	3
374	Control charts for evaluation of quality of low-dose-rate brachytherapy for prostate cancer. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 354-363.	0.4	1
375	Risk-adaptive paradigm for focal versus whole-gland salvage treatment for radio-recurrent prostate cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
376	Definitions of â€œcureâ€ after LDR-brachytherapy in low- and intermediate-risk prostate cancer - Phoenix or surgical?. <i>Advances in Radiation Oncology</i> , 2022, , 101112.	0.6	0
377	CT-guided Radioactive 125I Seed Implantation for Abdominal Incision Metastases of Colorectal Cancer: Safety and Efficacy in 17 Patients. <i>Clinical Colorectal Cancer</i> , 2022, , .	1.0	1
378	Overcoming pubic arch interference in prostate brachytherapy using steerable needles. <i>Journal of Contemporary Brachytherapy</i> , 2022, 14, 495-500.	0.4	1
380	Sarcopenia and excess visceral fat accumulation negatively affect early urinary function after iâ€125 lowâ€doseâ€rate brachytherapy for localized prostate cancer. <i>International Journal of Urology</i> , 0, , .	0.5	0
381	Validation of the bladder neck as an important organ at risk in prostate seed brachytherapy based on D2cc: A single-institution, retrospective review. <i>Journal of Contemporary Brachytherapy</i> , 0, , .	0.4	0
382	Prostate-specific Antigen Levels Following Brachytherapy Impact Late Biochemical Recurrence in Japanese Patients With Localized Prostate Cancer. <i>In Vivo</i> , 2023, 37, 738-746.	0.6	0

#	ARTICLE	IF	CITATIONS
383	Improving Quality of Life with Brachytherapy for Urological Malignancies. <i>Clinical Oncology</i> , 2023, 35, 516-523.	0.6	2
384	A Contemporary Report of Low-Dose-Rate Brachytherapy for Prostate Cancer Using MRI for Risk Stratification: Disease Outcomes and Patient-Reported Quality of Life. <i>Cancers</i> , 2023, 15, 1336.	1.7	3
385	Health Services Research in Brachytherapy: Current Understanding and Future Challenges. <i>Clinical Oncology</i> , 2023, , .	0.6	1
397	The role of GammaTile in the treatment of brain tumors: a technical and clinical overview. <i>Journal of Neuro-Oncology</i> , 2024, 166, 203-212.	1.4	0